Allison Bratzel
Stock Analyst at Piper Sandler
(1.84)
# 1341
Out of 5,370 analysts
40
Total ratings
56.67%
Success rate
21.82%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
REPL Replimune Group | Maintains: Overweight | 14 22 | 9.89 | 122.45% | 2 | Jun 2, 2025 | |
TYRA Tyra Biosciences | Assumes: Overweight | 33 | 10.29 | 220.7% | 1 | May 21, 2025 | |
RARE Ultragenyx Pharmaceu... | Maintains: Overweight | 140 115 | 36.63 | 213.95% | 1 | Mar 17, 2025 | |
AKBA Akebia Therapeutics | Maintains: Overweight | 4 6 | 3.54 | 69.49% | 1 | Mar 14, 2025 | |
INZY Inozyme Pharma | Maintains: Overweight | 30 23 | 3.99 | 476.44% | 1 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 26 | 3.25 | 700% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 620 725 | 544.81 | 33.07% | 13 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 12 22 | 14.46 | 52.14% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 23 | 20.25 | 13.58% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 62 | 35.43 | 74.99% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 42 | 31.52 | 33.25% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 22 | 11.02 | 99.64% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 4 | 2.38 | 68.07% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 8 20 | 4.87 | 310.68% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 20 | 3.27 | 511.62% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 23 25 | n/a | n/a | 1 | Apr 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 | 70.43 | 41.98% | 2 | Feb 8, 2023 |